Documente Academic
Documente Profesional
Documente Cultură
Voltas
Results Update
Voltas (VOLT IN) reported net loss of Rs1.16 bn, which includes Rs2.77 bn towards onerous contract (upward revision in the estimates cost of Sidra medical project due to design changes and delays) Net sales was at Rs11.6 bn in 3Q FY12, up 12% y-y, better than our estimates of Rs10.4 bn. We reiterate our BUY rating with a 12-month PT of Rs112 (unchanged). Our PT is based on 12x FY13E earnings (unchanged). We will revise our numbers once we get clarity on existing contracts post conference call Slowdown continues: The electro-mechanic projects (EMPS) segment reported revenue of Rs8.2 bn, up 19.0% y-y. EBIT of the EMPS segment was up 37% y-y, and an EBIT margin of 7.3% y-y, up 95 bp. Revenue of unitary cooling products (UCP) segment was up 18.7% y-y to Rs2.3 bn, with an EBIT of Rs143 mn, down 25% y-y. EBIT margin was at 6.1%, down 358 bp due to the slowdown in sales and high fixed operating and advertisement costs. Revenue of the EPS segment was down 39% y-y and EBIT was at Rs166 mn, down 34% y-y. We will revise our numbers post conference call Orderbook improves marginally: Total orderbook stands at Rs50.9 bn, up 9% y-y. The domestic electro-mechanical business has seen good orders in the health sector. Valuation: Voltas has reported loss of Rs2.77 bn towards onerous contract (upward revision in the estimates cost of Sidra medical project due to design changes and delays) for Sidra medical project in Qatar. The total value of this project for Voltas was over Rs10 bn, the contract is expected to complete by 4Q FY12. The long term business prospects in Middle East remain good and Voltas has recently formed JV in KSA and Oman to expand its reach. We reiterate our BUY rating with a revised 12-month PT of Rs112. Our PT is based on 12x FY13E earnings. We will revise our numbers once we get clarity on existing contracts post conference call Risks: Business may be negatively affected due to the global slowdown, especially in the Middle East, thereby increasing competition in the domestic and overseas markets. An increase in steel/metal prices could have an adverse impact on margin.
BUY
Reuters: VOLT.BO
Rs95
Bloomberg: VOLT IN
Rs112
Rs31.3 bn (US$634 mn) Rs189/71 331 mn 1826 (000) Rs164 mn (US$3.3 mn)
Apr-11
Jun-11
Aug-11
Oct-11
Dec-11
Source: Bloomberg
Exhibit 1:
YE March FY09 FY10 FY11 FY12E FY13E
Note: pricing as on 14 February 2012; Source: Company data, quant Global Research estimates
3Q FY12 results
3QFY12 11,647 7,983 68.5 1,628 14.0 1,162 10.0 2,766 13,539 (1,892) (16.2) 164 84 (1,812) 64 172 (1,704) 32 (544) 6 (1,154) (1,271) NA 3Q FY11 10,424 7,053 67.7 1,444 13.9 1,133 10.9 9,629 795 7.6 131 54 872 34 155 993 30 302 17 708 553 1.7 871 663 2.0 NA NA NA NA 2QFY12 11,021 8,112 73.6 1,355 12.3 843 7.7 10,310 711 6.5 223 75 859 60 250 1,049 17 178 25.0 55.3 (307.7) 86.8 (26.3) 12.0 (310.9) 5.7 40.6 NA 31.3 NA 2.5 37.7 12.7 20.2 y-y (%) 11.7 13.2 q-q (%) 5.7 (1.6)
Exhibit 3:
Rs mn Sales
Segmental analysis
3QFY12 11,539 8,241 877 2,338 85 901 602 166 143 (9) 7.8 7.3 18.9 6.1 (10.4) 71.4 7.6 20.3 0.7 3Q FY11 10,395 6,926 1,428 1,969 72 889 440 250 191 9 8.5 6.4 17.5 9.7 12.0 66.6 13.7 18.9 0.7 2QFY12 11,021 7,623 1,202 2,110 86 282 50 178 61 (7) 2.6 0.7 14.8 2.9 (8.4) 69.2 10.9 19.1 0.8 y-y (bp) 94.7 141.7 (357.7) q-q (bp) 664.5 409.6 319.0 y-y (%) 11.0 19.0 (38.6) 18.7 17.7 1.4 36.7 (33.6) (25.1) q-q (%) 4.7 8.1 (27.0) 10.8 NA 219.7 1,107.8 (6.8) 132.2
El ectro Mecha ni ca l Projects Engi neeri ng Products Uni ta ry Cool i ng Products Others EBIT El ectro Mecha ni ca l Projects Engi neeri ng Products Uni ta ry Cool i ng Products Others EBIT margin (%) El ectro Mecha ni ca l Projects Engi neeri ng Products Uni ta ry Cool i ng Products Others Sales breakdown (%) El ectro Mecha ni ca l Projects Engi neeri ng Products Uni ta ry Cool i ng Products Others
Source: Company data, quant Global Research
Profitability trend
Revenue 3Q FY12 Consensus 6,061 8,773 1,851 6,103 10,563 Change y-y (%) Est/Act* 5,833 7,925 1,697 6,267 11,647 3Q FY12 2Q FY12 (3.9) 17.0 11.2 35.6 11.7 (12.2) 39.4 17.1 51.0 (0.9) 1Q FY12 4Q FY11 6.6 40.8 25.1 39.8 (4.3) 6.3 47.8 (9.6) NA 13.1 3.1 37.1 (8.6) NA 5.3 PAT (adj) 3Q FY12 (57) 1,472 211 212 315 Change y-y (%) (328) 1,513 230 147 (1,271) PL 23.5 40.1 (26.1) NA PL 22.3 39.2 67.3 (0.7) (73.9) 29.3 72.5 271.3 (0.5) (27.5) 32.5 (23.4) NA (32.2) (33.5) 10.3 1.6 NA (16.6) EBITDA Margin (%) 3Q FY12 2.6 20.4 27.9 11.7 5.7 (1.6) 23.0 30.8 9.7 (16.2) 1.3 19.7 35.0 11.5 2.3 3.7 21.1 28.0 11.8 8.1 10.5 20.1 13.7 20.7 8.4 6.7 23.2 24.4 11.2 7.6
3Q FY11 Consensus Est/Act* 3Q FY12 2Q FY12 1Q FY12 4Q FY11 3Q FY11 Consensus Est/Act* 2Q FY12 1Q FY12 4Q FY11 3Q FY11
Key financials
Exhibit 5:
Net revenues Expenditure Ra w ma teri a l s Empl oyee expens es Other expendi ture EBITDA Other i ncome Depreci a ti on EBIT Interes t expens e Extra ordi na ry Income / (Los s ) PBT Ta xes Mi nori ty Interes t i n profi ts Reported PAT Adjusted PAT EPS (Rs) Outs ta ndi ng Sha res (mn) Cash flow statement Cash flow from operating activity PBT Add: Depreci a ti on Add: Interes t Les s : ta xes pa i d Add: other a djus tments Les s : worki ng ca pi ta l cha nges Total operating cash flows Opera ti ng CF wi thout WC cha nges Cash flow from investing activity Ca pi ta l expendi ture Cha nge i n i nves tments Total investing cash flow Cash flow from financing activity Sha re i s s ua nces Cha nge i n borrowi ngs Di vi dend Interes t pa yment Total financing cash flow Net change in cash Openi ng ca s h & CE Cl os i ng ca s h & CE 0 1,077 (619) (127) 330 1,569 3,002 4,571 0 (1,463) (774) (98) (2,335) 119 4,571 4,689 1,030 (774) (165) 90 291 4,689 4,980 166 (967) (280) (1,081) (193) 4,980 4,787 168 (967) (196) (995) (1,527) 4,787 3,260 (758) 1,023 265 35 (777) (742) (362) (274) (636) (442) 73 (369) (489) (102) (591) 3,719 210 127 (1,172) (192) (1,718) 974 2,692 5,318 214 98 (1,472) (436) (527) 3,196 3,722 5,245 210 165 (1,729) (43) (3,012) 836 3,848 4,405 344 280 (1,345) (2,427) 1,256 3,684 4,889 256 196 (1,564) (3,717) 59 3,777 Key Ratios Effecti ve ta x ra te (%) EBITDA ma rgi n (%) EBIT ma rgi n (%) PAT Ma rgi n (%) Debt to equi ty (x) EPS (Rs ) Ca s h EPS (Rs ) Book Va l ue (Rs ) Valuation Ratios ROa E (%) ROa CE (%) P/BV (x) PE Ra ti o (x) EV/EBITDA (x) Growth metrics (%) Revenue EBITDA Net profi t EPS 35.1 11.9 27.9 27.9 11.1 62.2 58.0 58.0 7.7 (4.0) (10.9) (10.9) 2.2 (26.2) (35.3) (35.3) 11.6 34.0 51.0 51.0 33.0 40.1 4.0 13.9 10.1 38.0 43.2 2.9 8.8 5.9 25.9 31.1 2.3 9.9 6.3 14.0 18.1 2.0 15.3 8.7 18.3 20.4 1.7 10.1 6.9 FY09 31.5 6.5 8.3 5.2 0.2 6.8 7.4 23.9 FY10 27.7 9.6 10.7 7.4 0.0 10.8 11.4 32.8 FY11 33.0 8.5 9.7 6.1 0.1 9.6 10.2 41.2 FY12E 30.5 6.1 6.8 3.9 0.1 6.2 7.2 47.7 FY13E 32.0 7.4 8.2 5.2 0.1 9.4 10.1 54.9
Income Statement
Note: pricing as on 14 February 2012; Source: Company data, quant Global Research estimates
40%
30%
10%
9%
We, Arafat Saiyed and Amber Singhania, hereby certify all of the views expressed in this report accurately reflect our personal views about the subject company or companies and its or their securities. We also certify that no part of our compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report."
quant Group generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, quant Group generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of clients of quant Group. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. quant Group does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions including those involving futures, options, and other derivatives as well as non investment-grade securities that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavor to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so. We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market maker or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis and may also perform or seek to perform investment banking or advisory services for or relating to those companies and may also be represented in the supervisory board or any other committee of those companies. For the purpose of calculating whether quant Group and its affiliates hold, beneficially own, or control, including the right to vote for directors, 1% or more of the equity shares of the subject, the holding of the issuer of a research report is also included. quant Group and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, affectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the current derivatives risk disclosure document before entering into any derivative transactions. In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this material may be (i) copied, photocopied, or duplicated in any form by any means or (ii) redistributed without quant Groups prior written consent. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.
612, maker chambers IV, nariman point, mumbai 400 021, india phone 91 22 4088 0100, 3025 0100 fax 91 22 4088 0198, 3025 0198
February 15, 2012 6